New Anticoagulants (Dabigatran, Apixaban, Rivaroxaban) for Stroke Prevention in Atrial Fibrillation

被引：6

作者：

Aguilar, Maria I. ^{[1
]}

Kuo, Ruth S. ^{[2
]}

Freeman, William D. ^{[3
,4
,5
]}

机构：

[1] Mayo Clin, Dept Neurol, Div Cerebrovasc Dis, Phoenix, AZ 85054 USA

[2] Scripps Mem Hosp, Dept Pharm, La Jolla, CA 92037 USA

[3] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA

[4] Mayo Clin, Dept Neurosurg, Jacksonville, FL 32224 USA

[5] Mayo Clin, Dept Crit Care, Jacksonville, FL 32224 USA

来源：

NEUROLOGIC CLINICS | 2013年 / 31卷 / 03期

关键词：

Anticoagulation; Stroke; Atrial fibrillation; Reversal; Direct thrombin inhibitors; Factor Xa inhibitors; Dabigatran; Rivaroxaban; Apixaban; Edoxaban; ORAL ANTICOAGULANTS; RISK STRATIFICATION; WARFARIN; REVERSAL; EFFICACY; SAFETY; CHA(2)DS(2)-VASC; THROMBIN; EDOXABAN; FOCUS;

D O I：

10.1016/j.ncl.2013.03.001

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

New oral anticoagulants have been found to be as efficacious as warfarin and safer in terms of intracranial bleeding. All patients with nonvalvular atrial fibrillation should receive antithrombotic therapy for stroke prevention. For those at low risk, antiplatelet therapy is probably sufficient. For those at intermediate or high risk, anticoagulation is superior to antiplatelet therapy. Four oral anticoagulants are currently approved for stroke and systemic embolism prevention in atrial fibrillation: warfarin, dabigatran, rivaroxaban, and apixaban. Management of bleeding complications while on the new agents remains an area of concern and management is based on anecdotal experience and observational studies.

引用

页码：659 / +

页数：18

共 32 条

[21] Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach The Euro Heart Survey on Atrial Fibrillation [J].

Lip, Gregory Y. H. ;

Nieuwlaat, Robby ;

Pisters, Ron ;

Lane, Deirdre A. ;

Crijns, Harry J. G. M. .

CHEST, 2010, 137 (02) :263-272

[22] Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) Versus Warfarin in Patients With Atrial Fibrillation [J].

Miller, Corey S. ;

Grandi, Sonia M. ;

Shimony, Avi ;

Filion, Kristian B. ;

Eisenberg, Mark J. .

AMERICAN JOURNAL OF CARDIOLOGY, 2012, 110 (03) :453-460

[23] The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: A nationwide cohort study [J].

Olesen, Jonas Bjerring ;

Torp-Pedersen, Christian ;

Hansen, Morten Lock ;

Lip, Gregory Y. H. .

THROMBOSIS AND HAEMOSTASIS, 2012, 107 (06) :1172-1179

[24] Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation [J].

Patel, Manesh R. ;

Mahaffey, Kenneth W. ;

Garg, Jyotsna ;

Pan, Guohua ;

Singer, Daniel E. ;

Hacke, Werner ;

Breithardt, Guenter ;

Halperin, Jonathan L. ;

Hankey, Graeme J. ;

Piccini, Jonathan P. ;

Becker, Richard C. ;

Nessel, Christopher C. ;

Paolini, John F. ;

Berkowitz, Scott D. ;

Fox, Keith A. A. ;

Califf, Robert M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (10) :883-891

[25] Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: Focus on Apixaban [J].

Potpara, Tatjana S. ;

Polovina, Marija M. ;

Licina, Marina M. ;

Stojanovic, Radan M. ;

Prostran, Milica S. ;

Lip, Gregory Y. H. .

ADVANCES IN THERAPY, 2012, 29 (06) :491-507

[26] Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48) [J].

Ruff, Christian T. ;

Giugliano, Robert P. ;

Antman, Elliott M. ;

Crugnale, Sharon E. ;

Bocanegra, Tomas ;

Mercuri, Michele ;

Hanyok, James ;

Patel, Indravadan ;

Shi, Minggao ;

Salazar, Dan ;

McCabe, Carolyn H. ;

Braunwald, Eugene .

AMERICAN HEART JOURNAL, 2010, 160 (04) :635-U266

[27] Comparative Efficacy and Safety of New Oral Anticoagulants in Patients With Atrial Fibrillation [J].

Schneeweiss, Sebastian ;

Gagne, Joshua J. ;

Patrick, Amanda R. ;

Choudhry, Niteesh K. ;

Avorn, Jerry .

CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2012, 5 (04) :480-486

[28] Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity [J].

van Ryn, Joanne ;

Stangier, Joachim ;

Haertter, Sebastian ;

Liesenfeld, Karl-Heinz ;

Wienen, Wolfgang ;

Feuring, Martin ;

Clemens, Andreas .

THROMBOSIS AND HAEMOSTASIS, 2010, 103 (06) :1116-1127

[29] Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial [J].

Wallentin, Lars ;

Yusuf, Salim ;

Ezekowitz, Michael D. ;

Alings, Marco ;

Flather, Marcus ;

Franzosi, Maria Grazia ;

Pais, Prem ;

Dans, Antonio ;

Eikelboom, John ;

Oldgren, Jonas ;

Pogue, Janice ;

Reilly, Paul A. ;

Yang, Sean ;

Connolly, Stuart J. .

LANCET, 2010, 376 (9745) :975-983

[30] 2011 ACCF/AHA/HRS Focused Update on the Management of Patients with Atrial Fibrillation (Update on Dabigatran): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [J].

Wann, L. Samuel ;

Curtis, Anne B. ;

Ellenbogen, Kenneth A. ;

Estes, N. A. Mark, III ;

Ezekowitz, Michael D. ;

Jackman, Warren M. ;

January, Craig T. ;

Lowe, James E. ;

Page, Richard L. ;

Slotwiner, David J. ;

Stevenson, William G. ;

Tracy, Cynthia M. .

CIRCULATION, 2011, 123 (10) :1144-1150

← 1 2 3 4 →